aTyr Pharma, Inc. (LIFE): Price and Financial Metrics
GET POWR RATINGS... FREE!
LIFE POWR Grades
- LIFE scores best on the Sentiment dimension, with a Sentiment rank ahead of 95.13% of US stocks.
- The strongest trend for LIFE is in Growth, which has been heading up over the past 26 weeks.
- LIFE ranks lowest in Momentum; there it ranks in the 8th percentile.
LIFE Stock Summary
- LIFE's price/sales ratio is 65.65; that's higher than the P/S ratio of 96.98% of US stocks.
- With a year-over-year growth in debt of -70.8%, aTYR PHARMA INC's debt growth rate surpasses just 4.41% of about US stocks.
- Revenue growth over the past 12 months for aTYR PHARMA INC comes in at -75.98%, a number that bests just 1.97% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to aTYR PHARMA INC are INFI, ZSAN, SONN, BBI, and DRRX.
- LIFE's SEC filings can be seen here. And to visit aTYR PHARMA INC's official web site, go to www.atyrpharma.com.
LIFE Valuation Summary
- In comparison to the median Healthcare stock, LIFE's price/sales ratio is 1015.79% higher, now standing at 42.4.
- Over the past 77 months, LIFE's price/earnings ratio has gone up 10.4.
- Over the past 77 months, LIFE's price/earnings ratio has gone up 10.4.
Below are key valuation metrics over time for LIFE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LIFE | 2021-08-31 | 42.4 | 2.3 | -3.2 | -3.2 |
| LIFE | 2021-08-30 | 42.2 | 2.3 | -3.2 | -3.2 |
| LIFE | 2021-08-27 | 40.9 | 2.2 | -3.1 | -3.1 |
| LIFE | 2021-08-26 | 39.9 | 2.1 | -3.0 | -3.0 |
| LIFE | 2021-08-25 | 40.3 | 2.2 | -3.1 | -3.0 |
| LIFE | 2021-08-24 | 39.1 | 2.1 | -3.0 | -2.9 |
LIFE Growth Metrics
- Its year over year net income to common stockholders growth rate is now at -59.92%.
- Its 4 year net cashflow from operations growth rate is now at 72.25%.
- The 4 year cash and equivalents growth rate now stands at -27.07%.
The table below shows LIFE's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 2.053 | -30.39 | -30.141 |
| 2021-06-30 | 2.201 | -24.475 | -29.073 |
| 2021-03-31 | 2.39 | -23.186 | -25.128 |
| 2020-12-31 | 10.455 | -15.301 | -16.224 |
| 2020-09-30 | 8.546 | -14.816 | -17.265 |
| 2020-06-30 | 8.582 | -13.514 | -16.311 |
LIFE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LIFE has a Quality Grade of C, ranking ahead of 43.43% of graded US stocks.
- LIFE's asset turnover comes in at 0.048 -- ranking 321st of 682 Pharmaceutical Products stocks.
- CBIO, ASMB, and CLSD are the stocks whose asset turnover ratios are most correlated with LIFE.
The table below shows LIFE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.048 | 1 | -0.965 |
| 2021-03-31 | 0.052 | 1 | -0.976 |
| 2020-12-31 | 0.229 | 1 | -0.842 |
| 2020-09-30 | 0.190 | 1 | -0.815 |
| 2020-06-30 | 0.189 | 1 | -0.709 |
| 2020-03-31 | 0.185 | 1 | -0.587 |
LIFE Price Target
For more insight on analysts targets of LIFE, see our LIFE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.40 | Average Broker Recommendation | 1.43 (Moderate Buy) |
LIFE Stock Price Chart Interactive Chart >
LIFE Price/Volume Stats
| Current price | $2.84 | 52-week high | $13.10 |
| Prev. close | $2.80 | 52-week low | $2.68 |
| Day low | $2.81 | Volume | 67,600 |
| Day high | $2.90 | Avg. volume | 135,223 |
| 50-day MA | $4.35 | Dividend yield | N/A |
| 200-day MA | $6.46 | Market Cap | 79.68M |
aTyr Pharma, Inc. (LIFE) Company Bio
aTyr Pharma, Inc. is a biotherapeutics company, engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology. aTyr research and development focuses on the extracellular functionality and signaling pathways of tRNA synthetases. Over the last ten years, the company has developed an international portfolio of intellectual property, including 20 human tRNA synthetases and over 300 protein compositions patented. Sanjay S. Shukla, M.D., M.S. has served as our President and Chief Executive Officer and as a board member since November 2017. aTyr’s headquarters is located in San Diego, California and the company employs 42 people.
Latest LIFE News From Around the Web
Below are the latest news stories about aTYR PHARMA INC that investors may wish to consider to help them evaluate LIFE as an investment opportunity.
Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue EstimatesProvention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day®Panel to take place on Monday, February 28, 2022, at 2:55pm EST / 11:55am PSTSAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a panel as part of the National Institutes of Health (NIH) Rare Disease Day® virtual conference on Monday, |
aTyr Pharma to Present at BIO CEO & Investor ConferenceSAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference, which is being held February 14 – 17, 2022, at the Marriott Marquis in New York, NY. |
Love Hemp Group PLC Announces Directorate ChangesDirectorate Changes - Garry Cook and Graham Mullis join BoardLONDON, UK / ACCESSWIRE / February 3, 2022 / Love Hemp Group PLC ("Love Hemp", the "Group", or the "Company") (AQSE:LIFE)(OTCQB:WRHLF), the brand-led consumer goods company focused on CBD health and wellness solutions, is pleased to announce that Garry Cook and Graham Mullis will be joining the Board of Love Hemp as Non-Executive Directors from 14 February 2022.These appointments are being made to support and enhance Love Hemp's corpor |
The past five years for aTyr Pharma (NASDAQ:LIFE) investors has not been profitableSome stocks are best avoided. We don't wish catastrophic capital loss on anyone. Anyone who held aTyr Pharma, Inc... |
LIFE Price Returns
| 1-mo | -31.73% |
| 3-mo | -42.74% |
| 6-mo | -65.95% |
| 1-year | -37.44% |
| 3-year | -52.49% |
| 5-year | -93.66% |
| YTD | -61.98% |
| 2021 | 92.53% |
| 2020 | -6.95% |
| 2019 | -39.95% |
| 2018 | -85.83% |
| 2017 | 62.79% |
Continue Researching LIFE
Want to see what other sources are saying about aTYR PHARMA INC's financials and stock price? Try the links below:aTYR PHARMA INC (LIFE) Stock Price | Nasdaq
aTYR PHARMA INC (LIFE) Stock Quote, History and News - Yahoo Finance
aTYR PHARMA INC (LIFE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...